NASDAQ:OMCLOmnicell Stock Price, Forecast & News

$66.90

-0.01 (-0.01 %)

(As of 06/2/2020 04:00 PM ET)

Add

Compare

Today's Range

$65.61

Now: $66.90▼

$67.83

50-Day Range

$59.36

MA: $68.39▼

$74.43

52-Week Range

$54.24

Now: $66.90▼

$94.85

Volume312,200 shs

Average Volume296,889 shs

Market Capitalization$2.85 billion

P/E Ratio41.81

Dividend YieldN/A

Beta1.02

Omnicell, Inc. provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides automated dispensing cabinets for medications and supplies used in nursing units, operating rooms, and emergency departments; analytics software to monitor drug diversion and address inventory management issues; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems used in hospitals and retail pharmacies for handling the stocking and retrieval of boxed medications. The Medication Adherence segment provides medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings; automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; and semi-automated filling equipment for the long-term care institutional pharmacy. It also offers Omnicell Patient Engagement, a subscription-based software system; patient communication tools, such as interactive voice response for pharmacies; and electronic Medication Administration Record software for use in nursing homes. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.

Beat the Market (BTM) Rank^™

3.3 Analyst's Opinion

Consensus Rating
Omnicell has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $85.00, Omnicell has a potential upside of 27.1% from its current price of $66.90.
Amount of Analyst Coverage
Omnicell has only been the subject of 3 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
Omnicell has received 453 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Omnicell has received 352 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Omnicell has received 56.27% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Omnicell and other stocks. Vote “Outperform” if you believe OMCL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OMCL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Omnicell does not currently pay a dividend.
Dividend Growth
Omnicell does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Omnicell insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $330,550.00 in company stock.
Percentage Held by Insiders
Only 2.63% of the stock of Omnicell is held by insiders.
Percentage Held by Institutions
95.89% of the stock of Omnicell is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Omnicell are expected to grow by 12.16% in the coming year, from $2.22 to $2.49 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Omnicell is 41.81, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.73.
Price to Earnings Ratio vs. Sector
The P/E ratio of Omnicell is 41.81, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.45.
Price to Earnings Growth Ratio
Omnicell has a PEG Ratio of 3.01. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Omnicell has a P/B Ratio of 3.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.54 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Electronic computers

Sub-IndustryHealth Care Technology

SectorMedical

Current SymbolNASDAQ:OMCL

Previous Symbol

CUSIP68213N10

CIK926326

Webwww.omnicell.com

Phone650-251-6100

Debt

Debt-to-Equity RatioN/A

Current Ratio1.93

Quick Ratio1.47

Price-To-Earnings

Trailing P/E Ratio41.81

Forward P/E Ratio30.14

P/E Growth3.01

Sales & Book Value

Annual Sales$897.03 million

Price / Sales3.18

Cash Flow$3.82 per share

Price / Cash Flow17.52

Book Value$20.16 per share

Price / Book3.32

Profitability

EPS (Most Recent Fiscal Year)$2.19

Net Income$61.34 million

Net Margins7.51%

Return on Equity11.37%

Return on Assets7.65%

Miscellaneous

Employees2,700

Outstanding Shares42,620,000

Market Cap$2.85 billion

Next Earnings Date7/23/2020 (Estimated)

OptionableOptionable

Receive OMCL News and Ratings via Email

Sign-up to receive the latest news and ratings for OMCL and its competitors with MarketBeat's FREE daily newsletter.

Omnicell (NASDAQ:OMCL) Frequently Asked Questions

How has Omnicell's stock been impacted by COVID-19 (Coronavirus)?

Omnicell's stock was trading at $77.41 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OMCL shares have decreased by 13.6% and is now trading at $66.90. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Omnicell?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Omnicell.

When is Omnicell's next earnings date?

Omnicell is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for Omnicell.

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) released its quarterly earnings data on Thursday, May, 7th. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.51 by $0.15. The firm earned $229.69 million during the quarter, compared to analyst estimates of $218.99 million. Omnicell had a return on equity of 11.37% and a net margin of 7.51%. Omnicell's revenue for the quarter was up 13.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.61 earnings per share. View Omnicell's earnings history.

What price target have analysts set for OMCL?

7 Wall Street analysts have issued 12-month price targets for Omnicell's stock. Their forecasts range from $76.00 to $100.00. On average, they anticipate Omnicell's stock price to reach $85.00 in the next year. This suggests a possible upside of 27.1% from the stock's current price. View analysts' price targets for Omnicell.

Has Omnicell been receiving favorable news coverage?

Media coverage about OMCL stock has been trending very negative on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Omnicell earned a daily sentiment score of -3.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutOmnicell.

Who are some of Omnicell's key competitors?

Some companies that are related to Omnicell include Cerner (CERN), HMS (HMSY), Cortexyme (CRTX), Allscripts Healthcare Solutions (MDRX), HealthStream (HSTM), Vocera Communications (VCRA) and Computer Programs & Systems (CPSI). View all competitors.

What other stocks do shareholders of Omnicell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Adobe (ADBE), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), NVIDIA (NVDA) and Applied Materials (AMAT).

Who are Omnicell's key executives?

Omnicell's management team includes the following people:

Mr. Randall A. Lipps, Founder, Exec. Chairman, Pres & CEO (Age 62)
Mr. Peter J. Kuipers, Exec. VP & CFO (Age 47)
Mr. Daniel S. Johnston, Exec. VP, Chief Legal & Admin. Officer and Corp. Sec. (Age 55)
Mr. Joseph Brian Spears, VP of Corp. Fin. & Chief Accounting Officer (Age 59)
Mr. Nhat H. Ngo, Exec. VP of Marketing, Strategy & Bus. Devel. (Age 46)

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Who are Omnicell's major shareholders?

Omnicell's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.10%), Wellington Management Group LLP (8.50%), Conestoga Capital Advisors LLC (3.91%), State Street Corp (3.06%), Bank of New York Mellon Corp (2.06%) and Eagle Asset Management Inc. (1.93%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, James T Judson, Joanne B Bauer, Jorge R Taborga, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann. View institutional ownership trends for Omnicell.

Which institutional investors are selling Omnicell stock?

OMCL stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Rice Hall James & Associates LLC, Rice Hall James & Associates LLC, Wellington Management Group LLP, Invesco Ltd., Summit Creek Advisors LLC, Fisher Asset Management LLC, and Global Alpha Capital Management Ltd.. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, Joanne B Bauer, Nhat H Ngo, Peter J Kuipers, Randall A Lipps, and Scott Peter Seidelmann. View insider buying and selling activity for Omnicell.

Which institutional investors are buying Omnicell stock?

OMCL stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Ziegler Capital Management LLC, State Street Corp, Waddell & Reed Financial Inc., JPMorgan Chase & Co., Conestoga Capital Advisors LLC, Fiera Capital Corp, and Pembroke Management LTD. View insider buying and selling activity for Omnicell.

How do I buy shares of Omnicell?

Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Omnicell's stock price today?

One share of OMCL stock can currently be purchased for approximately $66.90.

How big of a company is Omnicell?

Omnicell has a market capitalization of $2.85 billion and generates $897.03 million in revenue each year. The company earns $61.34 million in net income (profit) each year or $2.19 on an earnings per share basis. Omnicell employs 2,700 workers across the globe.

What is Omnicell's official website?

The official website for Omnicell is www.omnicell.com.

How can I contact Omnicell?

Omnicell's mailing address is 590 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at ir.omnicell.com.

This page was last updated on 6/2/2020 by MarketBeat.com Staff